Suramin in Adrenal Cancer: Modulation of Steroid Hormone Production, Cytotoxicityin Vitro, and Clinical Antitumor Effect*
| Autor: | R. V. La Rocca, Charles E. Myers, C. A. Jamis-Dow, Romano Danesi, Cy A. Stein, G. H. Weiss |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Suramin medicine.medical_treatment Clinical Biochemistry Antineoplastic Agents Biology Biochemistry Cell Line Mice Endocrinology Internal medicine Adrenal Glands Tumor Cells Cultured medicine Animals Humans Adrenocortical carcinoma Hormone metabolism ANTITUMOR EFFICACY preclinical model Tumor Stem Cell Assay Aged Mice Inbred BALB C Adrenal gland suramin clinical study cytotoxicity Biochemistry (medical) Middle Aged medicine.disease Antiparasitic agent Adrenal Cortex Neoplasms Hormones Steroid hormone medicine.anatomical_structure Mineralocorticoid Female Steroids Glucocorticoid medicine.drug |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 71:497-504 |
| ISSN: | 1945-7197 0021-972X |
| Popis: | Suramin, a drug known to have antiparasitic effects, has been previously shown to have adrenocorticolytic activity in primates. We now confirm preferential accumulation of this compound in the normal adrenal gland, evaluate its in vitro effect against two human adrenocortical carcinoma cell lines (SW-13 and NCI-H295), and report the clinical activity of suramin in 17 patients with metastatic adrenocortical carcinoma. Inhibition of colony formation occurred in both adrenal cell lines in vitro at concentrations that are clinically achievable in humans. In addition, suramin concentrations as low as 100 micrograms/mL were able to inhibit glucocorticoid, mineralocorticoid, and androgen production by the NCI-H295 cell line. Of 16 patients with adrenocortical carcinoma now evaluable for tumor response, 2 achieved a partial response, 2 had a minor response, and 5 remained with stable disease for periods ranging from 3-10 months; the remainder progressed. One of 7 patients with excessive steroid hormone production achieved a partial normalization of her steroid levels for the duration of suramin therapy in the setting of radiographic disease stabilization. An additional patient treated off-study for lack of radiographically measurable disease, achieved complete normalization of plasma aldosterone levels. We conclude that suramin preferentially accumulates in adrenal cells, induces cytotoxicity and significant down-regulation of steroid hormone production in vitro, and has some therapeutic efficacy as a single agent in patients with metastatic adrenocortical carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|